Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:D-galactopyranose
go back to main search page
Accession:CHEBI:4139 term browser browse the term
Definition:A galactopyranose having D-configuration.
Synonyms:related_synonym: D-Galactose;   Formula=C6H12O6;   InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3+,4+,5-,6?/m1/s1;   InChIKey=WQZGKKKJIJFFOK-SVZMEOIVSA-N;   SMILES=OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O
 xref: Beilstein:1281605;   CAS:10257-28-0;   CAS:59-23-4;   GlyTouCan:G68158BT;   Gmelin:83257;   KEGG:C00124;   KNApSAcK:C00019681;   PMID:1378088;   PMID:17336832;   PMID:19913595;   PMID:28709133;   Reaxys:1281605;   Wikipedia:Galactose


show annotations for term's descendants           Sort by:
 
1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cxcl10 C-X-C motif chemokine ligand 10 increases expression ISO KRN 7000 results in increased expression of CXCL10 protein CTD PMID:15867097 NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
JBrowse link
G Il12b interleukin 12B increases expression ISO KRN 7000 results in increased expression of IL12B protein CTD PMID:15867097 NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
JBrowse link
2-amino-2-deoxy-D-galactopyranose term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acta2 actin alpha 2, smooth muscle increases expression
multiple interactions
EXP Galactosamine results in increased expression of ACTA2 mRNA; Galactosamine results in increased expression of ACTA2 protein
Genistein inhibits the reaction [Galactosamine results in increased expression of ACTA2 mRNA]; Genistein inhibits the reaction [Galactosamine results in increased expression of ACTA2 protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of ACTA2 protein]
CTD PMID:27836788, PMID:27876602 NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
JBrowse link
G Actb actin, beta increases expression EXP Galactosamine results in increased expression of ACTB mRNA CTD PMID:22563491 NCBI chr12:13,715,843...13,718,813
Ensembl chr12:13,715,843...13,718,841
JBrowse link
G Afp alpha-fetoprotein increases expression EXP Galactosamine results in increased expression of AFP protein CTD PMID:61145, PMID:16965562 NCBI chr14:19,141,755...19,159,919
Ensembl chr14:19,141,755...19,159,923
JBrowse link
G Alb albumin multiple interactions
decreases expression
increases expression
EXP [ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of IL10 protein; [ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of TNF protein
Galactosamine results in decreased expression of ALB protein
Galactosamine results in increased expression of ALB mRNA
CTD PMID:17963606, PMID:18779383, PMID:22310181 NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
JBrowse link
G Ambp alpha-1-microglobulin/bikunin precursor increases expression EXP Galactosamine results in increased expression of AMBP mRNA CTD PMID:18779383 NCBI chr 5:78,975,690...78,986,021
Ensembl chr 5:78,975,678...78,985,990
JBrowse link
G Apoe apolipoprotein E decreases expression EXP Galactosamine results in decreased expression of APOE protein CTD PMID:6631239 NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions EXP 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 protein CTD PMID:28844859 NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
JBrowse link
G Atm ATM serine/threonine kinase increases expression
multiple interactions
EXP Galactosamine results in increased expression of ATM protein
glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of ATM protein]
CTD PMID:24565947 NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression
ISO
EXP
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form]
Galactosamine results in increased expression of BAX mRNA; Galactosamine results in increased expression of BAX protein
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX mRNA; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of BAX mRNA]
CTD PMID:20558151, PMID:20850421, PMID:21401295, PMID:22118634, PMID:24565947 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases expression
ISO
EXP
[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of BCL2 protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of BCL2 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form]
glycine propionyl carnitine inhibits the reaction [Galactosamine results in decreased expression of BCL2 mRNA]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of BCL2 protein]
Galactosamine results in decreased expression of BCL2 mRNA; Galactosamine results in decreased expression of BCL2 protein
CTD PMID:20558151, PMID:20850421, PMID:22118634, PMID:24565947 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BID mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of BID protein CTD PMID:12907702, PMID:21401295 NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
JBrowse link
G Casp1 caspase 1 multiple interactions ISO [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP1 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP1 protein] CTD PMID:32453893 NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
JBrowse link
G Casp3 caspase 3 multiple interactions
increases expression
increases activity
ISO
EXP
3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP3 protein]; [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein; [Galactosamine co-treated with Endotoxins] results in increased activity of CASP3 protein; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP3 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; [Nitric Oxide Donors results in increased abundance of Nitric Oxide] inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]; [TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form]; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein]; Biliverdine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]]; Dithiothreitol inhibits the reaction [Nitric Oxide Donors inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]]; gentiopicroside inhibits the reaction [[[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein modified form]; Melatonin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein]; Methylene Chloride inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP3 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form]; TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein]
[Galactosamine co-treated with TNF protein] results in increased activity of CASP3 protein; alpha-Tocopherol inhibits the reaction [Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein]; Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein; Ketoconazole inhibits the reaction [Galactosamine results in increased activity of CASP3 protein]; Rifampin promotes the reaction [Galactosamine results in increased activity of CASP3 protein]
Galactosamine results in increased expression of CASP3 mRNA; Galactosamine results in increased expression of CASP3 protein
2-Acetylaminofluorene inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of CASP3 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of CASP3 protein; Alprostadil inhibits the reaction [Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein]; Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of CASP3 mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of CASP3 protein]
CTD PMID:9388267, PMID:12907702, PMID:14512878, PMID:15486963, PMID:15565661, PMID:15610455, PMID:17602819, PMID:17936189, PMID:20558151, PMID:20850421, PMID:21146893, PMID:21401295, PMID:22023962, PMID:22118634, PMID:22310181, PMID:24565947, PMID:24830863, PMID:26176423, PMID:28887131, PMID:31332890, PMID:32453893 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp7 caspase 7 multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP7 protein; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP7 protein] CTD PMID:21146893 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
JBrowse link
G Casp8 caspase 8 multiple interactions ISO 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP8 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP8 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP8 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP8 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP8 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP8 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP8 protein modified form]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP8 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP8 protein] CTD PMID:20558151, PMID:20850421, PMID:21146893, PMID:24830863, PMID:31332890 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Casp9 caspase 9 multiple interactions
increases expression
ISO
EXP
3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP9 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP9 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP9 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP9 protein; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP9 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP9 protein modified form]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP9 protein]
mangiferin inhibits the reaction [Galactosamine results in increased expression of CASP9 protein]
CTD PMID:20558151, PMID:22118634, PMID:24830863, PMID:31332890 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Cat catalase multiple interactions
increases activity
decreases activity
ISO
EXP
6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased activity of CAT protein]; [Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased activity of CAT protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein; Caffeine inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein]; Oligopeptides inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]
Galactosamine results in increased activity of CAT protein
Galactosamine results in decreased activity of CAT protein
[Ascorbic Acid co-treated with beta Carotene co-treated with alpha-Tocopherol co-treated with Sodium Selenite] inhibits the reaction [Galactosamine results in increased activity of CAT protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in decreased activity of CAT protein]
CTD PMID:19153979, PMID:22154906, PMID:27836788, PMID:30236599, PMID:31022331, PMID:32453893 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CCL2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CCL2 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein] CTD PMID:21146893, PMID:28887131 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein] CTD PMID:21146893 NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein; Indomethacin promotes the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein]; nimesulide promotes the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein] CTD PMID:22107987 NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein; baicalein inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein]; Silymarin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein] CTD PMID:20850421 NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
JBrowse link
G Chuk component of inhibitor of nuclear factor kappa B kinase complex increases phosphorylation
multiple interactions
EXP Galactosamine results in increased phosphorylation of CHUK protein
mangiferin inhibits the reaction [Galactosamine results in increased phosphorylation of CHUK protein]
CTD PMID:22310181 NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
JBrowse link
G Col1a1 collagen type I alpha 1 chain increases expression
multiple interactions
EXP Galactosamine results in increased expression of COL1A1 mRNA
Genistein inhibits the reaction [Galactosamine results in increased expression of COL1A1 mRNA]
CTD PMID:27876602 NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
JBrowse link
G Col3a1 collagen type III alpha 1 chain multiple interactions
increases expression
EXP Genistein inhibits the reaction [Galactosamine results in increased expression of COL3A1 mRNA] CTD PMID:27876602 NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217
JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A multiple interactions
decreases expression
ISO alpha-Tocopherol inhibits the reaction [Galactosamine results in decreased expression of CPT1A mRNA] CTD PMID:17936189 NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions ISO [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL2 mRNA; [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL2 protein CTD PMID:15576625 NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions ISO [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL1 mRNA; [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL1 protein CTD PMID:15576625 NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
JBrowse link
G Cyba cytochrome b-245 alpha chain multiple interactions ISO [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CYBA protein; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CYBA protein] CTD PMID:28887131 NCBI chr19:55,249,634...55,257,824
Ensembl chr19:55,249,616...55,257,876
JBrowse link
G Cycs cytochrome c, somatic multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in increased localization of CYCS protein; [Lipopolysaccharides co-treated with Galactosamine] affects the localization of CYCS protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of CYCS protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased localization of CYCS protein] CTD PMID:20558151, PMID:20850421 NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 decreases expression EXP Galactosamine results in decreased expression of CYP1A2 protein CTD PMID:16208626 NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 decreases expression EXP Galactosamine results in decreased expression of CYP2E1 protein CTD PMID:16208626 NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions EXP 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of DDIT3 mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of DDIT3 mRNA CTD PMID:28844859 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha multiple interactions EXP 4-phenylbutyric acid affects the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased phosphorylation of EIF2S1 protein]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of EIF2S1 mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of and results in decreased phosphorylation of EIF2S1 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of EIF2S1 mRNA CTD PMID:28844859 NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit multiple interactions ISO [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GCLM mRNA CTD PMID:28887131 NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions
increases expression
EXP
ISO
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein; Genistein inhibits the reaction [Galactosamine results in increased expression of GPT protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of GPT protein]
(2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]]; (2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]]; 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]; 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein; [Galactosamine co-treated with Lipopolysaccharides] promotes the reaction [idelalisib results in increased expression of ALT protein]; [Galactosamine co-treated with Lipopolysaccharides] promotes the reaction [Miransertib results in increased expression of ALT protein]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of GPT protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of GPT protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein; Acetylcysteine inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of GPT protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; Plant Extracts inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of GPT protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein]; stattic inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]
CTD PMID:19153979, PMID:24565947, PMID:24830863, PMID:25620059, PMID:27876602, PMID:28844859, PMID:28887131, PMID:30236599, PMID:30822415, PMID:31332890, PMID:31445927, PMID:32453893 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G H3f4 H3.4 histone increases expression EXP Galactosamine results in increased expression of H3F4 mRNA CTD PMID:11779202 NCBI chr10:45,304,696...45,305,106 JBrowse link
G Habp2 hyaluronan binding protein 2 increases activity ISO Galactosamine results in increased activity of HABP2 protein CTD PMID:11510480 NCBI chr 1:277,068,715...277,104,567
Ensembl chr 1:277,068,761...277,104,566
JBrowse link
G Hbegf heparin-binding EGF-like growth factor multiple interactions ISO [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA] CTD PMID:28887131 NCBI chr18:29,330,302...29,340,185
Ensembl chr18:29,329,764...29,340,403
JBrowse link
G Hgf hepatocyte growth factor multiple interactions EXP 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF protein]; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF protein CTD PMID:28844859 NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
decreases expression
ISO
EXP
Galactosamine inhibits the reaction [cobaltiprotoporphyrin results in increased expression of HMOX1 mRNA]
Galactosamine results in decreased expression of HMOX1 protein
[[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HMOX1 mRNA] which results in increased chemical synthesis of Bilirubin; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HMOX1 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA; mangiferin inhibits the reaction [Galactosamine results in decreased expression of HMOX1 protein]; resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]
CTD PMID:14512878, PMID:19796704, PMID:21401295, PMID:22310181 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions EXP 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 protein CTD PMID:28844859 NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO Galactosamine analog inhibits the reaction [TNF results in increased expression of ICAM1 protein] CTD PMID:16431966 NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
JBrowse link
G Ifng interferon gamma multiple interactions
increases expression
ISO
EXP
[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG mRNA]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein]
mangiferin inhibits the reaction [Galactosamine results in increased expression of IFNG mRNA]
CTD PMID:15486963, PMID:22310181 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 increases expression EXP Galactosamine results in increased expression of IGFBP1 mRNA CTD PMID:11779202 NCBI chr14:87,448,716...87,453,783
Ensembl chr14:87,448,692...87,453,785
JBrowse link
G Ikbkb inhibitor of nuclear factor kappa B kinase subunit beta multiple interactions
increases phosphorylation
EXP mangiferin inhibits the reaction [Galactosamine results in increased phosphorylation of IKBKB protein] CTD PMID:22310181 NCBI chr16:74,177,233...74,230,809
Ensembl chr16:74,177,215...74,230,815
JBrowse link
G Il10 interleukin 10 multiple interactions
decreases expression
ISO
EXP
[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein]
Galactosamine results in decreased expression of IL10 mRNA
[ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of IL10 protein; mangiferin inhibits the reaction [Galactosamine results in decreased expression of IL10 mRNA]
CTD PMID:15486963, PMID:17963606, PMID:22310181 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Il12b interleukin 12B multiple interactions
increases expression
ISO
EXP
[LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA
mangiferin inhibits the reaction [Galactosamine results in increased expression of IL12B mRNA]
CTD PMID:19913045, PMID:22310181 NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
JBrowse link
G Il18 interleukin 18 increases expression
multiple interactions
ISO
EXP
Galactosamine results in increased expression of IL18 mRNA; Galactosamine results in increased expression of IL18 protein
mangiferin inhibits the reaction [Galactosamine results in increased expression of IL18 mRNA]
[LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; Plant Preparations inhibits the reaction [Galactosamine results in increased expression of IL18 mRNA]; Plant Preparations inhibits the reaction [Galactosamine results in increased expression of IL18 protein]
CTD PMID:19913045, PMID:20102673, PMID:22310181 NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases expression
EXP
ISO
Genistein inhibits the reaction [Galactosamine results in increased expression of IL1B mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of IL1B mRNA]
2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein]]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]
CTD PMID:15135310, PMID:22310181, PMID:25620059, PMID:28887131, PMID:30550845, PMID:32453893 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il6 interleukin 6 multiple interactions
increases expression
ISO
EXP
3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]
Galactosamine results in increased expression of IL6 mRNA
glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of IL6 mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of IL6 mRNA]
CTD PMID:15135310, PMID:15486963, PMID:22310181, PMID:24830863, PMID:27836788, PMID:28887131, PMID:31332890, PMID:32453893 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Irak1 interleukin-1 receptor-associated kinase 1 multiple interactions ISO [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of IRAK1 protein; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]] CTD PMID:28213090 NCBI chr  X:156,716,469...156,726,367
Ensembl chr  X:156,716,604...156,725,977
JBrowse link
G Lcat lecithin cholesterol acyltransferase decreases activity EXP Galactosamine results in decreased activity of LCAT protein CTD PMID:6631239 NCBI chr19:37,913,333...37,916,799
Ensembl chr19:37,913,336...37,916,813
JBrowse link
G Lep leptin multiple interactions
increases response to substance
ISO [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEP gene mutant form results in increased susceptibility to Galactosamine] CTD PMID:19913045 NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
JBrowse link
G Lepr leptin receptor multiple interactions
increases response to substance
ISO [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEPR gene mutant form results in increased susceptibility to Galactosamine] CTD PMID:19913045 NCBI chr 5:120,503,475...120,682,281
Ensembl chr 5:120,564,645...120,682,221
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation
ISO
EXP
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased phosphorylation of MAPK1 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK1 protein modified form; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK1 protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form]
Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of MAPK1 protein]
CTD PMID:20558151, PMID:20850421, PMID:25620059, PMID:28887131 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation
ISO
EXP
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased phosphorylation of MAPK3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK3 protein modified form; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK3 protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form]
Galactosamine results in increased phosphorylation of MAPK3 protein
Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of MAPK3 protein]
CTD PMID:20558151, PMID:20850421, PMID:25620059, PMID:28887131 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions EXP
ISO
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of MET mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of MET mRNA
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of MET mRNA
CTD PMID:28844859, PMID:28887131 NCBI chr 4:44,747,467...44,854,628
Ensembl chr 4:44,774,741...44,852,665
JBrowse link
G Mpo myeloperoxidase multiple interactions
increases activity
ISO
EXP
(2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein]]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of MPO protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of MPO protein]
Galactosamine results in increased activity of MPO protein
[Ascorbic Acid co-treated with beta Carotene co-treated with alpha-Tocopherol co-treated with Sodium Selenite] inhibits the reaction [Galactosamine results in increased activity of MPO protein]
CTD PMID:28887131, PMID:30550845, PMID:31022331, PMID:32453893 NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
JBrowse link
G Ndufb6 NADH:ubiquinone oxidoreductase subunit B6 multiple interactions
decreases expression
ISO Acetylcysteine inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA]; coenzyme Q10 inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA] CTD PMID:19523936 NCBI chr 5:56,567,109...56,576,676
Ensembl chr 5:56,567,109...56,576,676
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 affects localization
increases activity
multiple interactions
decreases expression
EXP
ISO
Galactosamine affects the localization of NFE2L2 protein
Galactosamine results in increased activity of NFE2L2 protein
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA]; Plant Extracts promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA]; Plant Extracts promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein]
mangiferin affects the reaction [Galactosamine affects the localization of NFE2L2 protein]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of NFE2L2 protein]
CTD PMID:22310181, PMID:28887131, PMID:30114225, PMID:30203046, PMID:30236599 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [NFKB1 protein binds to NFKB1 protein]]; alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein]]; Galactosamine results in increased activity of [NFKB1 protein binds to NFKB1 protein]; Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein] CTD PMID:17936189 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions
decreases expression
EXP
ISO
Alprostadil inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein]; Enzyme Inhibitors inhibits the reaction [Alprostadil inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein]]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein]
[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA protein modified form; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA protein modified form]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein]
CTD PMID:15565661, PMID:20850421, PMID:22310181, PMID:28213090, PMID:30550845 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions ISO [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NLRP3 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NLRP3 protein] CTD PMID:32453893 NCBI chr10:45,884,324...45,918,290
Ensembl chr10:45,893,018...45,918,254
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions
increases expression
ISO
EXP
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein]
Galactosamine results in increased expression of NOS2 mRNA
alpha-Tocopherol inhibits the reaction [Galactosamine results in increased expression of NOS2 mRNA]
Galactosamine results in increased expression of NOS2 mRNA; Galactosamine results in increased expression of NOS2 promoter; Galactosamine results in increased expression of NOS2 protein
[[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitrites; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NOS2 mRNA; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 mRNA]; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 promoter]; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; Enzyme Inhibitors inhibits the reaction [Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]]; Galactosamine promotes the reaction [Alprostadil results in increased expression of NOS2 protein]; Genistein inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; mangiferin inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NOS2 mRNA]
CTD PMID:15189274, PMID:15565661, PMID:17936189, PMID:19796704, PMID:21401295, PMID:22107987, PMID:22118634, PMID:22310181, PMID:25620059 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 decreases expression
multiple interactions
EXP
ISO
Galactosamine results in decreased expression of NQO1 protein
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NQO1 mRNA
mangiferin inhibits the reaction [Galactosamine results in decreased expression of NQO1 protein]
CTD PMID:22310181, PMID:28887131 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein; gentiopicroside inhibits the reaction [[[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein] CTD PMID:20558151 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha increases expression
multiple interactions
increases activity
decreases expression
ISO Galactosamine results in increased expression of PPARA mRNA
[Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA mRNA; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA protein; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA mRNA; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA protein
Galactosamine results in increased activity of PPARA protein
alpha-Tocopherol inhibits the reaction [Galactosamine results in decreased expression of PPARA mRNA]
CTD PMID:17936189, PMID:25689681, PMID:30203046, PMID:30236599 NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG protein; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG mRNA; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG protein; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG mRNA; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG protein; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG protein] CTD PMID:30236599, PMID:30550845 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Ppia peptidylprolyl isomerase A decreases expression EXP Galactosamine results in decreased expression of CYCA mRNA CTD PMID:22563491 NCBI chr14:86,673,775...86,677,443
Ensembl chr14:86,673,775...86,677,443
JBrowse link
G Ptgs1 prostaglandin-endoperoxide synthase 1 multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA] CTD PMID:22107987 NCBI chr 3:15,560,685...15,582,339
Ensembl chr 3:15,560,712...15,582,344
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
increases expression
ISO
EXP
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PTGS2 protein; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PTGS2 protein]
Genistein inhibits the reaction [Galactosamine results in increased expression of PTGS2 protein]
CTD PMID:22107987, PMID:25620059, PMID:32453893 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Ptn pleiotrophin increases expression EXP Galactosamine results in increased expression of PTN mRNA; Galactosamine results in increased expression of PTN protein CTD PMID:12057922 NCBI chr 4:64,239,156...64,330,996
Ensembl chr 4:64,239,158...64,330,996
JBrowse link
G Pttg1 PTTG1 regulator of sister chromatid separation, securin affects response to substance EXP PTTG1 mRNA affects the susceptibility to Galactosamine CTD PMID:19800905 NCBI chr10:29,014,332...29,026,088
Ensembl chr10:29,020,049...29,026,002
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
increases expression
ISO
EXP
[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA protein modified form; [Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein]
alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein]]; Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein]
mangiferin inhibits the reaction [Galactosamine results in increased expression of RELA protein]
CTD PMID:17936189, PMID:20850421, PMID:22310181, PMID:30550845 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Sdc3 syndecan 3 increases expression EXP Galactosamine results in increased expression of SDC3 mRNA CTD PMID:12057922 NCBI chr 5:148,923,098...148,956,404
Ensembl chr 5:148,923,098...148,956,404
JBrowse link
G Serpine1 serpin family E member 1 increases expression EXP Galactosamine results in increased expression of SERPINE1 mRNA CTD PMID:11779202 NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
JBrowse link
G Sesn2 sestrin 2 multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of SESN2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of SESN2 protein CTD PMID:25637945 NCBI chr 5:150,684,891...150,703,846
Ensembl chr 5:150,684,133...150,704,117
JBrowse link
G Smad2 SMAD family member 2 multiple interactions
increases phosphorylation
EXP Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of SMAD2 protein] CTD PMID:27876602 NCBI chr18:72,550,107...72,612,078
Ensembl chr18:72,550,219...72,612,078
JBrowse link
G Smad3 SMAD family member 3 multiple interactions
increases phosphorylation
EXP Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of SMAD3 protein] CTD PMID:27876602 NCBI chr 8:68,569,530...68,678,349
Ensembl chr 8:68,569,530...68,678,349
JBrowse link
G Smad7 SMAD family member 7 multiple interactions
decreases expression
EXP Genistein inhibits the reaction [Galactosamine results in decreased expression of SMAD7 protein] CTD PMID:27876602 NCBI chr18:71,395,830...71,424,164
Ensembl chr18:71,395,830...71,424,157
JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of SOD1 mRNA CTD PMID:21401295 NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
JBrowse link
G Sord sorbitol dehydrogenase multiple interactions ISO [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of SORD protein; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of SORD protein] CTD PMID:30822415 NCBI chr 3:114,176,127...114,207,368
Ensembl chr 3:114,176,309...114,207,366
JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions ISO [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 protein]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEP gene mutant form results in increased susceptibility to Galactosamine]; SPP1 promotes the reaction [LEPR gene mutant form results in increased susceptibility to Galactosamine] CTD PMID:19913045 NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein] CTD PMID:28887131 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Stat5b signal transducer and activator of transcription 5B decreases activity ISO Galactosamine results in decreased activity of STAT5B protein CTD PMID:30114225 NCBI chr10:88,686,207...88,712,313
Ensembl chr10:88,686,207...88,754,829
JBrowse link
G Tgfb1 transforming growth factor, beta 1 increases expression
multiple interactions
EXP Galactosamine results in increased expression of TGFB1 mRNA; Galactosamine results in increased expression of TGFB1 protein
Genistein inhibits the reaction [Galactosamine results in increased expression of TGFB1 mRNA]; Genistein inhibits the reaction [Galactosamine results in increased expression of TGFB1 protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TGFB1 protein]
CTD PMID:27836788, PMID:27876602 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions ISO [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TLR4 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TLR4 protein] CTD PMID:32453893 NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases expression
ISO
EXP
2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]]; 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; [Nitric Oxide Donors results in increased abundance of Nitric Oxide] inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]; [TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]]; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF protein]; Dithiothreitol inhibits the reaction [Nitric Oxide Donors inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA]; hydroquinone metabolite inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; Prednisolone inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF mRNA]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]
Galactosamine results in increased expression of TNF mRNA; Galactosamine results in increased expression of TNF protein
[Galactosamine co-treated with TNF protein] results in increased activity of CASP3 protein; Galactosamine analog inhibits the reaction [TNF results in increased expression of ICAM1 protein]
[ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of TNF protein; Alprostadil promotes the reaction [Galactosamine results in increased expression of TNF protein]; Genistein inhibits the reaction [Galactosamine results in increased expression of TNF protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TNF mRNA]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TNF protein]; mangiferin inhibits the reaction [Galactosamine results in increased expression of TNF mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of TNF protein]
CTD PMID:9388267, PMID:10221824, PMID:11779202, PMID:14512878, PMID:15135310, PMID:15486963, PMID:16431966, PMID:17602819, PMID:17963606, PMID:20054000, PMID:20558151, PMID:22107987, PMID:22118634, PMID:22310181, PMID:24565947, PMID:24830863, PMID:25620059, PMID:26176423, PMID:27836788, PMID:28213090, PMID:28887131, PMID:30550845, PMID:30822415, PMID:31332890, PMID:32453893 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Traf6 TNF receptor associated factor 6 multiple interactions ISO [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]] CTD PMID:28213090 NCBI chr 3:91,252,829...91,271,607
Ensembl chr 3:91,252,829...91,271,607
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions EXP 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of VEGFA mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of VEGFA mRNA CTD PMID:28844859 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
G Xiap X-linked inhibitor of apoptosis multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein; baicalein inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein]; Silymarin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein] CTD PMID:20850421 NCBI chr  X:128,409,425...128,455,786
Ensembl chr  X:128,409,472...128,453,000
JBrowse link
4-methylumbelliferyl beta-D-galactoside term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ca12 carbonic anhydrase 12 decreases activity ISO 4-methylumbelliferyl-galactopyranoside analog results in decreased activity of CA12 protein CTD PMID:22077347 NCBI chr 8:72,405,770...72,461,425
Ensembl chr 8:72,405,748...72,460,240
JBrowse link
G Ca9 carbonic anhydrase 9 decreases activity ISO 4-methylumbelliferyl-galactopyranoside analog results in decreased activity of CA9 protein CTD PMID:22077347 NCBI chr 5:59,008,277...59,015,535
Ensembl chr 5:59,008,933...59,015,528
JBrowse link
alpha-D-galactose term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ache acetylcholinesterase increases activity
multiple interactions
ISO Galactose results in increased activity of ACHE protein
catalpol inhibits the reaction [Galactose results in increased activity of ACHE protein]
CTD PMID:23612000 NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
JBrowse link
G Ager advanced glycosylation end product-specific receptor increases expression ISO Galactose results in increased expression of AGER mRNA; Galactose results in increased expression of AGER protein CTD PMID:22687555 NCBI chr20:4,363,152...4,366,079
Ensembl chr20:4,363,152...4,366,079
JBrowse link
G Aif1 allograft inflammatory factor 1 increases expression
multiple interactions
ISO Galactose results in increased expression of AIF1 protein
lycopene inhibits the reaction [Galactose results in increased expression of AIF1 protein]
CTD PMID:28974442 NCBI chr20:5,161,350...5,167,176
Ensembl chr20:5,161,333...5,166,448
JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B multiple interactions
increases expression
ISO protocatechuic acid inhibits the reaction [Galactose results in increased expression of AKR1B3 mRNA] CTD PMID:22687555 NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956
JBrowse link
G Aox1 aldehyde oxidase 1 increases expression
multiple interactions
ISO Galactose results in increased expression of AOX1 mRNA
sodium bisulfide inhibits the reaction [Galactose results in increased expression of AOX1 mRNA]
CTD PMID:23274001 NCBI chr 9:64,929,682...65,007,872
Ensembl chr 9:64,929,721...65,007,870
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO [Galactose co-treated with Glucose deficiency] promotes the reaction [leflunomide results in increased expression of ATF4 protein] CTD PMID:29427785 NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
JBrowse link
G Atg7 autophagy related 7 decreases expression
multiple interactions
EXP
ISO
Galactose results in decreased expression of ATG7 protein
MIR34A mRNA promotes the reaction [Galactose results in decreased expression of ATG7 protein]
CTD PMID:28302704 NCBI chr 4:146,570,113...146,777,093
Ensembl chr 4:146,598,413...146,777,124
JBrowse link
G Atox1 antioxidant 1 copper chaperone decreases expression
multiple interactions
ISO Galactose results in decreased expression of ATOX1 mRNA
sodium bisulfide inhibits the reaction [Galactose results in decreased expression of ATOX1 mRNA]
CTD PMID:23274001 NCBI chr10:40,790,850...40,805,886
Ensembl chr10:40,790,845...40,805,941
JBrowse link
G Atp5f1a ATP synthase F1 subunit alpha multiple interactions EXP [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of ATP5F1A protein CTD PMID:25997894 NCBI chr18:74,156,553...74,164,490
Ensembl chr18:74,156,553...74,164,495
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression
ISO
EXP
Phycocyanin inhibits the reaction [Galactose results in increased expression of BAX protein]
Saponins inhibits the reaction [Galactose results in increased expression of BAX protein]
CTD PMID:23036742, PMID:25892055 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases expression
ISO
EXP
Phycocyanin inhibits the reaction [Galactose results in decreased expression of BCL2 protein]
Saponins inhibits the reaction [Galactose results in decreased expression of BCL2 protein]
CTD PMID:23036742, PMID:25892055 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bdnf brain-derived neurotrophic factor decreases expression
multiple interactions
ISO Galactose results in decreased expression of BDNF mRNA; Galactose results in decreased expression of BDNF protein
lycopene inhibits the reaction [Galactose results in decreased expression of BDNF mRNA]; lycopene inhibits the reaction [Galactose results in decreased expression of BDNF protein]
CTD PMID:28974442 NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
JBrowse link
G Becn1 beclin 1 multiple interactions
decreases expression
EXP [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in decreased expression of BECN1 protein]
Galactose results in decreased expression of BECN1 protein
CTD PMID:25997894, PMID:28302704 NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
JBrowse link
G Casp3 caspase 3 increases cleavage
multiple interactions
increases activity
ISO
EXP
Galactose results in increased cleavage of CASP3 protein
[Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]
pioglitazone inhibits the reaction [Galactose results in increased activity of CASP3 protein]
Phycocyanin inhibits the reaction [Galactose results in increased cleavage of CASP3 protein]
CTD PMID:23036742, PMID:23795773, PMID:25997894 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp9 caspase 9 multiple interactions EXP [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased activity of CASP9 protein] CTD PMID:25997894 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Cat catalase increases activity
multiple interactions
EXP Galactose results in increased activity of CAT protein
Quercetin inhibits the reaction [Galactose results in increased activity of CAT protein]
CTD PMID:17211565 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Ccn2 cellular communication network factor 2 increases expression
multiple interactions
EXP Galactose results in increased expression of CCN2 protein
fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased expression of CCN2 protein]
CTD PMID:30367734 NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
JBrowse link
G Chat choline O-acetyltransferase multiple interactions
decreases activity
ISO catalpol inhibits the reaction [Galactose results in decreased activity of CHAT protein] CTD PMID:23612000 NCBI chr16:8,576,858...8,686,131
Ensembl chr16:8,577,840...8,686,131
JBrowse link
G Chrm1 cholinergic receptor, muscarinic 1 multiple interactions
decreases expression
ISO catalpol inhibits the reaction [Galactose results in decreased expression of CHRM1 protein] CTD PMID:23612000 NCBI chr 1:224,869,087...224,885,101
Ensembl chr 1:224,882,439...224,884,205
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions
increases expression
ISO [Galactose co-treated with Glucose deficiency] promotes the reaction [leflunomide results in increased expression of DDIT3 protein]; Phycocyanin inhibits the reaction [Galactose results in increased expression of DDIT3 protein] CTD PMID:23036742, PMID:29427785 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Dnm1l dynamin 1-like increases expression
multiple interactions
ISO
EXP
Galactose results in increased expression of DNM1L protein
MIR34A mRNA promotes the reaction [Galactose results in increased expression of DNM1L protein]
CTD PMID:28302704 NCBI chr11:88,830,968...88,882,271
Ensembl chr11:88,830,957...88,880,198
JBrowse link
G Fgf2 fibroblast growth factor 2 multiple interactions
increases expression
EXP fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased expression of FGF2 protein] CTD PMID:30367734 NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
JBrowse link
G Galk1 galactokinase 1 multiple interactions
increases metabolic processing
ISO [GALK1 protein results in increased metabolism of Galactose] which results in increased abundance of galactose-1-phosphate CTD PMID:20696150 NCBI chr10:104,560,322...104,564,499
Ensembl chr10:104,560,303...104,564,480
JBrowse link
G Gap43 growth associated protein 43 decreases expression
multiple interactions
ISO Galactose results in decreased expression of GAP43 mRNA
Quercetin inhibits the reaction [Galactose results in decreased expression of GAP43 mRNA]
CTD PMID:16707173 NCBI chr11:58,624,198...58,717,916
Ensembl chr11:58,624,198...58,717,914
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit decreases expression
multiple interactions
EXP Galactose results in decreased expression of GCLC mRNA
Saponins inhibits the reaction [Galactose results in decreased expression of GCLC mRNA]
CTD PMID:25892055 NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
JBrowse link
G Glo1 glyoxalase 1 multiple interactions ISO Galactose results in decreased expression of and results in decreased activity of GLO1 protein; protocatechuic acid inhibits the reaction [Galactose results in decreased expression of and results in decreased activity of GLO1 protein] CTD PMID:22687555 NCBI chr20:9,273,589...9,291,608
Ensembl chr20:9,273,594...9,291,610
JBrowse link
G Gss glutathione synthetase multiple interactions
decreases expression
ISO sodium bisulfide inhibits the reaction [Galactose results in decreased expression of GSS mRNA] CTD PMID:23274001 NCBI chr 3:151,076,254...151,106,557
Ensembl chr 3:151,076,254...151,106,557
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions ISO Galactose affects the reaction [Fusaric Acid affects the expression of HIF1A protein] CTD PMID:31654802 NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
decreases expression
EXP
ISO
Saponins inhibits the reaction [Galactose results in decreased expression of HMOX1 mRNA]
lycopene inhibits the reaction [Galactose results in decreased expression of HMOX1 mRNA]
CTD PMID:25892055, PMID:28974442 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions
increases expression
ISO Phycocyanin inhibits the reaction [Galactose results in increased expression of HSPA5 protein] CTD PMID:23036742 NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
JBrowse link
G Ifnb1 interferon beta 1 multiple interactions ISO [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactose] results in increased expression of IFNB1 protein; scoparone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactose] results in increased expression of IFNB1 protein] CTD PMID:23535186 NCBI chr 5:106,865,192...106,865,746
Ensembl chr 5:106,865,192...106,865,746
JBrowse link
G Il1b interleukin 1 beta increases expression
multiple interactions
increases secretion
ISO Galactose results in increased expression of IL1B protein
catalpol inhibits the reaction [Galactose results in increased expression of IL1B protein]; lycopene inhibits the reaction [Galactose results in increased expression of IL1B protein]; protocatechuic acid inhibits the reaction [Galactose results in increased secretion of IL1B protein]
CTD PMID:22687555, PMID:23612000, PMID:28974442 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il6 interleukin 6 multiple interactions
increases secretion
ISO [Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IL6 protein; protocatechuic acid inhibits the reaction [Galactose results in increased secretion of IL6 protein]; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IL6 protein]
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Galactose results in increased secretion of IL6 protein]; ginsenoside F1 inhibits the reaction [Galactose results in increased secretion of IL6 protein]; ginsenoside M1 inhibits the reaction [Galactose results in increased secretion of IL6 protein]; ginsenoside Rg3 inhibits the reaction [Galactose results in increased secretion of IL6 protein]; ginsenoside Rh1 inhibits the reaction [Galactose results in increased secretion of IL6 protein]; ginsenoside Rh2 inhibits the reaction [Galactose results in increased secretion of IL6 protein]
CTD PMID:22687555, PMID:23535186, PMID:29412148 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Irf3 interferon regulatory factor 3 multiple interactions ISO [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactose] results in increased phosphorylation of IRF3 protein; scoparone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactose] results in increased phosphorylation of IRF3 protein] CTD PMID:23535186 NCBI chr 1:100,992,244...100,997,202
Ensembl chr 1:100,992,405...100,997,198
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactose] affects the localization of and results in increased expression of JUN protein modified form; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] affects the localization of and results in increased expression of JUN protein modified form] CTD PMID:23535186 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Lct lactase increases hydrolysis EXP LCT protein results in increased hydrolysis of Galactose CTD PMID:14701853 NCBI chr13:44,998,414...45,040,593
Ensembl chr13:44,998,414...45,040,593
JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases phosphorylation
multiple interactions
EXP Galactose results in increased phosphorylation of MAPK1 protein
fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased phosphorylation of MAPK1 protein]
CTD PMID:30367734 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 increases phosphorylation
multiple interactions
EXP Galactose results in increased phosphorylation of MAPK3 protein
fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased phosphorylation of MAPK3 protein]
CTD PMID:30367734 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mfn2 mitofusin 2 increases expression
multiple interactions
EXP
ISO
Galactose results in increased expression of MFN2 protein
MIR34A mRNA promotes the reaction [Galactose results in increased expression of MFN2 protein]
CTD PMID:28302704 NCBI chr 5:164,684,244...164,715,414
Ensembl chr 5:164,684,509...164,714,145
JBrowse link
G Mir34a microRNA 34a increases expression
multiple interactions
EXP
ISO
Galactose results in increased expression of MIR34A mRNA
MIR34A mRNA promotes the reaction [Galactose results in decreased expression of ATG7 protein]; MIR34A mRNA promotes the reaction [Galactose results in increased expression of DNM1L protein]; MIR34A mRNA promotes the reaction [Galactose results in increased expression of MFN2 protein]; MIR34A mRNA promotes the reaction [Galactose results in increased expression of SQSTM1 protein]
CTD PMID:28302704 NCBI chr 5:167,092,491...167,092,592
Ensembl chr 5:167,092,491...167,092,592
JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions
increases activity
EXP fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased activity of MMP2 protein] CTD PMID:30367734 NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions EXP fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased expression of and results in increased activity of MMP9 protein]; Galactose results in increased expression of and results in increased activity of MMP9 protein CTD PMID:30367734 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Mt-co1 mitochondrially encoded cytochrome c oxidase I multiple interactions EXP [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of COX1 protein CTD PMID:25997894 NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
JBrowse link
G Mt-nd4 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4 affects metabolic processing ISO ND4 protein affects the metabolism of Galactose CTD PMID:8662757 NCBI chr MT:10,160...11,537
Ensembl chr MT:10,160...11,537
JBrowse link
G Mt-nd6 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6 affects metabolic processing ISO ND6 protein affects the metabolism of Galactose CTD PMID:9707444 NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061
JBrowse link
G Myd88 MYD88, innate immune signal transduction adaptor multiple interactions ISO [Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of MYD88 protein; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of MYD88 protein] CTD PMID:23535186 NCBI chr 8:128,022,512...128,027,462
Ensembl chr 8:128,022,473...128,026,841
JBrowse link
G Ndufb8 NADH:ubiquinone oxidoreductase subunit B8 multiple interactions EXP [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of NDUFB8 protein CTD PMID:25997894 NCBI chr 1:264,298,671...264,303,712
Ensembl chr 1:264,298,669...264,303,762
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 affects localization
multiple interactions
EXP Galactose affects the localization of NFE2L2 protein
Saponins inhibits the reaction [Galactose affects the localization of NFE2L2 protein]
CTD PMID:25892055 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 increases expression ISO Galactose results in increased expression of NFKB1 mRNA; Galactose results in increased expression of NFKB1 protein CTD PMID:22687555 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions
increases expression
increases activity
ISO Oligopeptides inhibits the reaction [Galactose results in increased activity of NOS2 protein]
Galactose results in increased expression of NOS2 mRNA
CTD PMID:23796539, PMID:28974442 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions
decreases expression
EXP
ISO
Saponins inhibits the reaction [Galactose results in decreased expression of NQO1 mRNA]
lycopene inhibits the reaction [Galactose results in decreased expression of NQO1 mRNA]
CTD PMID:25892055, PMID:28974442 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
G Oat ornithine aminotransferase multiple interactions EXP Galactose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein] CTD PMID:2827574 NCBI chr 1:204,562,289...204,582,070
Ensembl chr 1:204,562,289...204,582,070
JBrowse link
G Pdk1 pyruvate dehydrogenase kinase 1 multiple interactions ISO Galactose affects the reaction [Fusaric Acid results in increased expression of PDK1 protein] CTD PMID:31654802 NCBI chr 3:58,530,870...58,561,494
Ensembl chr 3:58,530,870...58,558,027
JBrowse link
G Pkm pyruvate kinase M1/2 multiple interactions ISO Galactose affects the reaction [Fusaric Acid results in increased expression of PKM mRNA] CTD PMID:31654802 NCBI chr 8:64,480,963...64,502,957
Ensembl chr 8:64,481,172...64,502,722
JBrowse link
G Plau plasminogen activator, urokinase increases expression
multiple interactions
EXP Galactose results in increased expression of PLAU protein
fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased expression of PLAU protein]
CTD PMID:30367734 NCBI chr15:3,644,296...3,650,765
Ensembl chr15:3,644,769...3,650,819
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha decreases expression EXP Galactose results in decreased expression of PPARGC1A protein CTD PMID:28302704 NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
increases expression
ISO Galactose results in increased expression of and results in increased activity of PTGS2 protein; lycopene inhibits the reaction [Galactose results in increased expression of PTGS2 mRNA]; protocatechuic acid inhibits the reaction [Galactose results in increased expression of PTGS2 mRNA]; protocatechuic acid inhibits the reaction [Galactose results in increased expression of PTGS2 protein] CTD PMID:22687555, PMID:28974442 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
affects localization
increases expression
ISO [Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] affects the localization of and results in increased expression of RELA protein; Galactose results in increased expression of and results in increased activity of RELA protein; protocatechuic acid inhibits the reaction [Galactose results in increased expression of and results in increased activity of RELA protein]; protocatechuic acid inhibits the reaction [Galactose results in increased expression of RELA mRNA]; protocatechuic acid inhibits the reaction [Galactose results in increased expression of RELA protein]; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] affects the localization of and results in increased expression of RELA protein]
ginsenoside F1 inhibits the reaction [Galactose affects the localization of RELA protein]; SB 203580 inhibits the reaction [Galactose affects the localization of RELA protein]
Galactose results in increased expression of RELA mRNA; Galactose results in increased expression of RELA protein
CTD PMID:22687555, PMID:23535186, PMID:29412148 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Sirt1 sirtuin 1 multiple interactions
decreases expression
EXP
ISO
Saponins inhibits the reaction [Galactose results in decreased expression of SIRT1 protein]
[Glucose deficiency co-treated with Galactose co-treated with Amino Acids co-treated with Pyruvic Acid] inhibits the reaction [resveratrol results in increased expression of SIRT1 protein]
CTD PMID:25892055, PMID:27358235, PMID:29426000 NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
JBrowse link
G Slc2a2 solute carrier family 2 member 2 increases transport ISO SLC2A2 protein results in increased transport of Galactose CTD PMID:8457197 NCBI chr 2:114,413,427...114,445,418
Ensembl chr 2:114,413,410...114,445,395
JBrowse link
G Slc2a3 solute carrier family 2 member 3 increases transport
multiple interactions
ISO SLC2A3 protein results in increased transport of Galactose
Galactose inhibits the reaction [SLC2A3 protein results in increased transport of Deoxyglucose]; Glucose inhibits the reaction [SLC2A3 protein results in increased transport of Galactose]; Maltose inhibits the reaction [SLC2A3 protein results in increased transport of Galactose]
CTD PMID:8457197 NCBI chr 4:155,549,991...155,626,018
Ensembl chr 4:155,408,233...155,631,856
JBrowse link
G Slc5a1 solute carrier family 5 member 1 multiple interactions
affects transport
ISO Galactose inhibits the reaction [[Sodium co-treated with SLC5A1 protein] results in increased uptake of methylglucoside]
SLC5A1 protein affects the transport of Galactose
CTD PMID:16300400, PMID:17288452 NCBI chr14:82,910,448...82,975,303
Ensembl chr14:82,909,981...82,975,263
JBrowse link
G Sod2 superoxide dismutase 2 decreases expression
multiple interactions
EXP Galactose results in decreased expression of SOD2 mRNA
Saponins inhibits the reaction [Galactose results in decreased expression of SOD2 mRNA]
CTD PMID:25892055 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
G Sord sorbitol dehydrogenase increases expression ISO Galactose results in increased expression of SORD mRNA CTD PMID:22687555 NCBI chr 3:114,176,127...114,207,368
Ensembl chr 3:114,176,309...114,207,366
JBrowse link
G Sp1 Sp1 transcription factor multiple interactions
increases expression
EXP fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased expression of SP1 protein] CTD PMID:30367734 NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions
increases expression
ISO
EXP
Hydroxychloroquine inhibits the reaction [Metformin inhibits the reaction [Galactose results in increased expression of SQSTM1 protein]]; Metformin inhibits the reaction [Galactose results in increased expression of SQSTM1 protein]; MIR34A mRNA promotes the reaction [Galactose results in increased expression of SQSTM1 protein] CTD PMID:28302704, PMID:29426000 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 increases expression ISO Galactose results in increased expression of SREBF1 mRNA CTD PMID:10913129 NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
JBrowse link
G Tfam transcription factor A, mitochondrial multiple interactions EXP [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of TFAM protein CTD PMID:25997894 NCBI chr20:18,594,057...18,606,106
Ensembl chr20:18,594,037...18,606,151
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions
increases expression
EXP fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased expression of TGFB1 protein] CTD PMID:30367734 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Ticam1 toll-like receptor adaptor molecule 1 multiple interactions ISO [Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TICAM1 protein; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TICAM1 protein] CTD PMID:23535186 NCBI chr 9:10,780,185...10,790,280 JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions ISO [Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TLR4 protein; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TLR4 protein] CTD PMID:23535186 NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases expression
increases secretion
ISO [Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein; catalpol inhibits the reaction [Galactose results in increased expression of TNF protein]; lycopene inhibits the reaction [Galactose results in increased expression of TNF protein]; protocatechuic acid inhibits the reaction [Galactose results in increased secretion of TNF protein]; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein] CTD PMID:22687555, PMID:23535186, PMID:23612000, PMID:28974442 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tp53 tumor protein p53 multiple interactions
increases expression
ISO
EXP
Phycocyanin inhibits the reaction [Galactose results in increased expression of TP53 protein]
[Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]
CTD PMID:23036742, PMID:25997894, PMID:29426000 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Txnip thioredoxin interacting protein multiple interactions
increases expression
ISO Hydroxychloroquine inhibits the reaction [Metformin inhibits the reaction [Galactose results in increased expression of TXNIP protein]]; Metformin inhibits the reaction [Galactose results in increased expression of TXNIP protein] CTD PMID:29426000 NCBI chr 2:198,683,168...198,686,971
Ensembl chr 2:198,683,159...198,686,974
JBrowse link
G Txnrd1 thioredoxin reductase 1 decreases expression
multiple interactions
ISO Galactose results in decreased expression of TXNRD1 mRNA
sodium bisulfide inhibits the reaction [Galactose results in decreased expression of TXNRD1 mRNA]
CTD PMID:23274001 NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
JBrowse link
alpha-D-galactose 1-phosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Galk1 galactokinase 1 multiple interactions ISO [Enzyme Inhibitors binds to and results in decreased activity of GALK1 protein] which results in decreased abundance of galactose-1-phosphate; [GALK1 protein results in increased metabolism of Galactose] which results in increased abundance of galactose-1-phosphate CTD PMID:20696150 NCBI chr10:104,560,322...104,564,499
Ensembl chr10:104,560,303...104,564,480
JBrowse link
kaempferol 3-O-beta-D-galactoside term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Pla2g2a phospholipase A2 group IIA affects activity ISO kaempferol-3-O-galactoside affects the activity of PLA2G2A protein CTD PMID:8190018 NCBI chr 5:157,282,650...157,285,295
Ensembl chr 5:157,282,669...157,285,328
JBrowse link
quercetin 3-O-beta-D-galactopyranoside term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ache acetylcholinesterase increases expression
multiple interactions
EXP hyperoside results in increased expression of ACHE mRNA
hyperoside results in increased expression of and results in increased activity of ACHE protein
CTD PMID:27019979 NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO
EXP
hyperoside inhibits the reaction [tert-Butylhydroperoxide affects the localization of BAX protein]
hyperoside inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX protein]
CTD PMID:18552516, PMID:31326407 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions EXP hyperoside inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] CTD PMID:31326407 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO [Quercetin co-treated with hyperoside] results in decreased expression of BIRC5 mRNA; [Quercetin co-treated with hyperoside] results in decreased expression of BIRC5 protein CTD PMID:24173369 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [Quercetin co-treated with hyperoside] results in increased cleavage of CASP3 protein CTD PMID:24173369, PMID:25354548 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Cat catalase multiple interactions EXP cyclopamine inhibits the reaction [hyperoside inhibits the reaction [Hydrogen Peroxide results in decreased activity of CAT protein]]; hyperoside inhibits the reaction [Hydrogen Peroxide results in decreased activity of CAT protein] CTD PMID:31326407 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Cycs cytochrome c, somatic multiple interactions ISO hyperoside inhibits the reaction [tert-Butylhydroperoxide affects the localization of CYCS protein] CTD PMID:18552516 NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 decreases activity
multiple interactions
ISO hyperoside results in decreased activity of CYP2E1 protein
hyperoside inhibits the reaction [Acetaminophen results in decreased activity of CYP2E1 protein]
CTD PMID:26772156 NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
JBrowse link
G Esr1 estrogen receptor 1 multiple interactions ISO hyperoside inhibits the reaction [Estradiol results in increased activity of ESR1 protein] CTD PMID:22613215 NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
JBrowse link
G Gli1 GLI family zinc finger 1 multiple interactions
increases expression
EXP hyperoside promotes the reaction [Hydrogen Peroxide results in increased expression of GLI1 mRNA]; hyperoside promotes the reaction [Hydrogen Peroxide results in increased expression of GLI1 protein]
hyperoside results in increased expression of GLI1 mRNA; hyperoside results in increased expression of GLI1 protein
CTD PMID:31326407 NCBI chr 7:70,620,794...70,633,171
Ensembl chr 7:70,620,766...70,630,338
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions ISO hyperoside inhibits the reaction [Acetaminophen results in increased activity of GPT protein] CTD PMID:26772156 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein] CTD PMID:30125551 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein] CTD PMID:30125551 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mir21 microRNA 21 multiple interactions ISO [Quercetin co-treated with hyperoside] results in decreased expression of MIR21 mRNA; MIR21 mRNA inhibits the reaction [[Quercetin co-treated with hyperoside] results in increased expression of PDCD4 mRNA]; MIR21 mRNA inhibits the reaction [[Quercetin co-treated with hyperoside] results in increased expression of PDCD4 protein]; MIR21 mRNA results in decreased susceptibility to [Quercetin co-treated with hyperoside] CTD PMID:25354548 NCBI chr10:73,902,210...73,902,301
Ensembl chr10:73,902,210...73,902,301
JBrowse link
G Mir27a microRNA 27a multiple interactions ISO [Quercetin co-treated with hyperoside] inhibits the reaction [MIR27A mRNA results in decreased expression of ZBTB10 mRNA]; [Quercetin co-treated with hyperoside] inhibits the reaction [MIR27A mRNA results in increased expression of SP1 mRNA]; [Quercetin co-treated with hyperoside] results in decreased expression of MIR27A mRNA; MIR27A mRNA inhibits the reaction [[Quercetin co-treated with hyperoside] results in increased expression of ZBTB10 mRNA] CTD PMID:24173369 NCBI chr19:25,318,736...25,318,822
Ensembl chr19:25,318,736...25,318,822
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 affects localization ISO hyperoside affects the localization of NFE2L2 protein CTD PMID:26772156 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein] CTD PMID:30125551 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression EXP Hyperoside increases expression of Nqo1 protein in liver RGD PMID:31399183 RGD:25823190 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [Quercetin co-treated with hyperoside] results in increased cleavage of PARP1 protein CTD PMID:24173369, PMID:25354548 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pdcd4 programmed cell death 4 multiple interactions ISO [Quercetin co-treated with hyperoside] results in increased expression of PDCD4 mRNA; [Quercetin co-treated with hyperoside] results in increased expression of PDCD4 protein; MIR21 mRNA inhibits the reaction [[Quercetin co-treated with hyperoside] results in increased expression of PDCD4 mRNA]; MIR21 mRNA inhibits the reaction [[Quercetin co-treated with hyperoside] results in increased expression of PDCD4 protein] CTD PMID:25354548 NCBI chr 1:274,616,625...274,648,204
Ensembl chr 1:274,625,224...274,648,204
JBrowse link
G Prima1 proline rich membrane anchor 1 increases expression EXP hyperoside results in increased expression of PRIMA1 mRNA CTD PMID:27019979 NCBI chr 6:127,075,954...127,127,985
Ensembl chr 6:127,075,954...127,127,413
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of RELA protein] CTD PMID:30125551 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Shh sonic hedgehog signaling molecule increases expression
multiple interactions
EXP hyperoside results in increased expression of SHH mRNA; hyperoside results in increased expression of SHH protein
hyperoside promotes the reaction [Hydrogen Peroxide results in increased expression of SHH mRNA]; hyperoside promotes the reaction [Hydrogen Peroxide results in increased expression of SHH protein]
CTD PMID:31326407 NCBI chr 4:718,538...727,691
Ensembl chr 4:718,538...727,691
JBrowse link
G Sirt1 sirtuin 1 multiple interactions ISO hyperoside inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of SIRT1 protein] CTD PMID:18552516 NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
JBrowse link
G Smo smoothened, frizzled class receptor increases expression
multiple interactions
EXP hyperoside results in increased expression of SMO mRNA; hyperoside results in increased expression of SMO protein
hyperoside promotes the reaction [Hydrogen Peroxide results in increased expression of SMO mRNA]; hyperoside promotes the reaction [Hydrogen Peroxide results in increased expression of SMO protein]
CTD PMID:31326407 NCBI chr 4:57,019,941...57,041,779
Ensembl chr 4:57,019,941...57,042,770
JBrowse link
G Sp1 Sp1 transcription factor multiple interactions ISO [Quercetin co-treated with hyperoside] inhibits the reaction [MIR27A mRNA results in increased expression of SP1 mRNA]; [Quercetin co-treated with hyperoside] results in decreased expression of SP1 mRNA; [Quercetin co-treated with hyperoside] results in decreased expression of SP1 protein CTD PMID:24173369 NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
JBrowse link
G Sp3 Sp3 transcription factor multiple interactions ISO [Quercetin co-treated with hyperoside] results in decreased expression of SP3 mRNA; [Quercetin co-treated with hyperoside] results in decreased expression of SP3 protein CTD PMID:24173369 NCBI chr 3:59,644,579...59,689,011
Ensembl chr 3:59,646,015...59,688,692
JBrowse link
G Sp4 Sp4 transcription factor multiple interactions ISO [Quercetin co-treated with hyperoside] results in decreased expression of SP4 mRNA; [Quercetin co-treated with hyperoside] results in decreased expression of SP4 protein CTD PMID:24173369 NCBI chr 6:146,135,877...146,201,344
Ensembl chr 6:146,135,877...146,195,819
JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 multiple interactions ISO hyperoside inhibits the reaction [Acetaminophen results in decreased expression of SULT1A1 mRNA] CTD PMID:26772156 NCBI chr 1:198,100,586...198,104,106
Ensembl chr 1:198,100,586...198,104,109
JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 multiple interactions
increases expression
ISO hyperoside inhibits the reaction [Acetaminophen results in decreased expression of SULT2A1 mRNA]
hyperoside results in increased expression of SULT2A1 mRNA
CTD PMID:26772156 NCBI chr 1:76,558,721...76,614,315
Ensembl chr 1:76,252,329...76,780,230
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO hyperoside inhibits the reaction [TNF protein results in increased expression of TNFRSF1A protein]; hyperoside inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; hyperoside inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein]; hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein]; hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of RELA protein] CTD PMID:30125551 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tnfrsf1a TNF receptor superfamily member 1A multiple interactions ISO hyperoside inhibits the reaction [TNF protein results in increased expression of TNFRSF1A protein] CTD PMID:30125551 NCBI chr 4:157,864,905...157,877,634
Ensembl chr 4:157,864,969...157,877,633
JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 multiple interactions
increases expression
ISO hyperoside inhibits the reaction [Acetaminophen results in decreased expression of UGT1A1 mRNA]
hyperoside results in increased expression of UGT1A1 mRNA
CTD PMID:26772156 NCBI chr 9:95,295,701...95,302,822
Ensembl chr 9:95,161,157...95,302,822
JBrowse link
G Ugt1a6 UDP glucuronosyltransferase family 1 member A6 multiple interactions ISO hyperoside inhibits the reaction [Acetaminophen results in decreased expression of UGT1A6 mRNA] CTD PMID:26772156 NCBI chr 9:95,241,609...95,302,822
Ensembl chr 9:95,161,157...95,302,822
JBrowse link
G Ugt2b17 UDP glucuronosyltransferase family 2 member B17 multiple interactions
increases expression
ISO hyperoside inhibits the reaction [Acetaminophen results in decreased expression of UGT2B1 mRNA]
hyperoside results in increased expression of UGT2B1 mRNA
CTD PMID:26772156 NCBI chr14:22,724,399...22,736,148
Ensembl chr14:22,724,070...22,825,444
JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions ISO hyperoside inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; hyperoside inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] CTD PMID:30125551 NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
JBrowse link
G Zbtb10 zinc finger and BTB domain containing 10 multiple interactions ISO [Quercetin co-treated with hyperoside] inhibits the reaction [MIR27A mRNA results in decreased expression of ZBTB10 mRNA]; [Quercetin co-treated with hyperoside] results in increased expression of ZBTB10 mRNA; MIR27A mRNA inhibits the reaction [[Quercetin co-treated with hyperoside] results in increased expression of ZBTB10 mRNA] CTD PMID:24173369 NCBI chr 2:94,692,939...94,730,976
Ensembl chr 2:94,692,939...94,730,978
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19816
    role 19764
      biological role 19764
        biochemical role 19313
          metabolite 19294
            fundamental metabolite 12621
              galactose 166
                D-galactose 166
                  D-galactopyranose 166
                    1-(D-glucopyranosyloxy)-3-hydroxypropan-2-yl D-galactopyranoside 0
                    1-O-(N-benzyloxycarbonylaminoethyl)-3-O-benzoyl-alpha-anthroside 0
                    2-amino-2-deoxy-D-galactopyranose + 91
                    2-aminoethyl 4,6-dideoxy-4-[(3-hydroxy-3-methylbutanoyl)amino]-2-O-methyl-alpha-D-glucoside 0
                    2-deoxy-2-fluoro-D-galactopyranose + 0
                    3,4-O-[(1S)-1-carboxyethylidene]-beta-D-galactose 0
                    4,6-O-[(1R)-1-carboxyethylidene]-D-galactose + 0
                    4-acetamido-4,6-dideoxy-D-galactose + 0
                    6-O-(trans-feruloyl)-D-galactopyranose 0
                    D-Galp-(1->3)-beta-D-Galp-(1->4)-D-Glcp 0
                    D-Galp-(1->4)-D-GlcpNAc + 0
                    D-Glcp-(1->2)-D-Galp 0
                    D-galactose 4-sulfate 0
                    D-galactose 6-sulfate + 0
                    N-benzyloxycarbonylaminoethyl-4-azido-3-O-benzoyl-2-O-methyl-4,6-dideoxy-alpha-D-glucopyranoside 0
                    alpha-D-Galf-(1->2)-D-Galp + 0
                    alpha-D-GalpNAc-(1->6)-D-Galp 0
                    alpha-D-Glcp-(1->2)-D-Galp 0
                    alpha-D-Glcp-(1->3)-D-Galp + 0
                    alpha-D-Manp-(1->2)-D-Galp + 0
                    alpha-D-Manp-(1->4)-D-Galp 0
                    alpha-D-Manp-(1->6)-D-Galp + 0
                    alpha-D-galactose + 77
                    alpha-L-Fucp-(1->3)-D-Galp + 0
                    alpha-L-Fucp-(1->4)-D-Galp 0
                    alpha-L-Fucp-(1->6)-D-Galp + 0
                    beta-D-Galf-(1->3)-D-Galp + 0
                    beta-D-Galp-(1->2)-D-Galp 0
                    beta-D-GalpNAc-(1->6)-D-Galp 0
                    beta-D-Glcp-(1->3)-D-Galp + 0
                    beta-D-GlcpNAc-(1->3)-D-Galp + 0
                    beta-D-GlcpNAc-(1->6)-D-Galp + 0
                    beta-D-Manp-(1->4)-D-Galp + 0
                    beta-D-galactopyranosyl D-galactopyranoside 0
                    beta-D-galactose + 40
                    beta-L-Fucp-(1->2)-D-Galp + 0
                    beta-L-Fucp-(1->3)-D-Galp + 0
                    beta-L-Fucp-(1->4)-D-Galp + 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19816
    subatomic particle 19814
      composite particle 19814
        hadron 19814
          baryon 19814
            nucleon 19814
              atomic nucleus 19814
                atom 19814
                  main group element atom 19702
                    p-block element atom 19702
                      carbon group element atom 19608
                        carbon atom 19597
                          organic molecular entity 19597
                            heteroorganic entity 19184
                              organochalcogen compound 18894
                                organooxygen compound 18816
                                  carbohydrates and carbohydrate derivatives 12191
                                    carbohydrate 12191
                                      monosaccharide 4035
                                        aldose 2548
                                          aldohexose 2192
                                            D-aldohexose 2186
                                              D-galactose 166
                                                D-galactopyranose 166
                                                  1-(D-glucopyranosyloxy)-3-hydroxypropan-2-yl D-galactopyranoside 0
                                                  1-O-(N-benzyloxycarbonylaminoethyl)-3-O-benzoyl-alpha-anthroside 0
                                                  2-amino-2-deoxy-D-galactopyranose + 91
                                                  2-aminoethyl 4,6-dideoxy-4-[(3-hydroxy-3-methylbutanoyl)amino]-2-O-methyl-alpha-D-glucoside 0
                                                  2-deoxy-2-fluoro-D-galactopyranose + 0
                                                  3,4-O-[(1S)-1-carboxyethylidene]-beta-D-galactose 0
                                                  4,6-O-[(1R)-1-carboxyethylidene]-D-galactose + 0
                                                  4-acetamido-4,6-dideoxy-D-galactose + 0
                                                  6-O-(trans-feruloyl)-D-galactopyranose 0
                                                  D-Galp-(1->3)-beta-D-Galp-(1->4)-D-Glcp 0
                                                  D-Galp-(1->4)-D-GlcpNAc + 0
                                                  D-Glcp-(1->2)-D-Galp 0
                                                  D-galactose 4-sulfate 0
                                                  D-galactose 6-sulfate + 0
                                                  N-benzyloxycarbonylaminoethyl-4-azido-3-O-benzoyl-2-O-methyl-4,6-dideoxy-alpha-D-glucopyranoside 0
                                                  alpha-D-Galf-(1->2)-D-Galp + 0
                                                  alpha-D-GalpNAc-(1->6)-D-Galp 0
                                                  alpha-D-Glcp-(1->2)-D-Galp 0
                                                  alpha-D-Glcp-(1->3)-D-Galp + 0
                                                  alpha-D-Manp-(1->2)-D-Galp + 0
                                                  alpha-D-Manp-(1->4)-D-Galp 0
                                                  alpha-D-Manp-(1->6)-D-Galp + 0
                                                  alpha-D-galactose + 77
                                                  alpha-L-Fucp-(1->3)-D-Galp + 0
                                                  alpha-L-Fucp-(1->4)-D-Galp 0
                                                  alpha-L-Fucp-(1->6)-D-Galp + 0
                                                  beta-D-Galf-(1->3)-D-Galp + 0
                                                  beta-D-Galp-(1->2)-D-Galp 0
                                                  beta-D-GalpNAc-(1->6)-D-Galp 0
                                                  beta-D-Glcp-(1->3)-D-Galp + 0
                                                  beta-D-GlcpNAc-(1->3)-D-Galp + 0
                                                  beta-D-GlcpNAc-(1->6)-D-Galp + 0
                                                  beta-D-Manp-(1->4)-D-Galp + 0
                                                  beta-D-galactopyranosyl D-galactopyranoside 0
                                                  beta-D-galactose + 40
                                                  beta-L-Fucp-(1->2)-D-Galp + 0
                                                  beta-L-Fucp-(1->3)-D-Galp + 0
                                                  beta-L-Fucp-(1->4)-D-Galp + 0
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.